These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33567829)

  • 41. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J
    Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
    Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
    Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.
    Sineke T; Evans D; Schnippel K; van Aswegen H; Berhanu R; Musakwa N; Lönnmark E; Long L; Rosen S
    Health Qual Life Outcomes; 2019 May; 17(1):94. PubMed ID: 31151398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Audiological monitoring of patients undergoing multidrug resistant tuberculosis treatment at Jigme Dorji Wangchuk National Referral Hospital and Gidakom Hospital, Bhutan.
    Wangchuk P; Ram Adhikari T; Nima G; Dendup P
    J Clin Tuberc Other Mycobact Dis; 2021 May; 23():100229. PubMed ID: 33898763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
    Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.
    Charan J; Reljic T; Kumar A
    Indian J Pharmacol; 2016; 48(2):186-91. PubMed ID: 27127322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Chesov D; Heyckendorf J; Alexandru S; Donica A; Chesov E; Reimann M; Crudu V; Botnaru V; Lange C
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
    Udwadia ZF; Amale RA; Mullerpattan JB
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bedaquiline: Current status and future perspectives.
    Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
    J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of medical interventions for reducing ototoxicity during treatment for multi-drug resistant tuberculosis.
    Khoza-Shangase K; Lecheko L; Ntlhakana L
    Acta Otorrinolaringol Esp (Engl Ed); 2020; 71(6):349-357. PubMed ID: 32517872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.